HLS Therapeutics (TSE:HLS) Shares Down 7.4% – Time to Sell?

HLS Therapeutics Inc. (TSE:HLS)’s share price traded down 7.4% during trading on Thursday. The stock traded as low as C$3.75 and last traded at C$3.89. 388,910 shares traded hands during mid-day trading, an increase of 1,077% from the average daily volume of 33,030 shares. The stock had previously closed at C$4.20.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on HLS. Raymond James Financial upgraded shares of HLS Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the stock from C$7.00 to C$8.00 in a research report on Friday, August 14th. Canaccord Genuity Group raised shares of HLS Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company. According to data from MarketBeat.com, HLS Therapeutics presently has an average rating of “Strong Buy” and an average price target of C$8.00.

HLS Therapeutics Price Performance

The company has a current ratio of 1.05, a quick ratio of 1.01 and a debt-to-equity ratio of 75.86. The firm has a market capitalization of C$120.34 million, a PE ratio of -14.41 and a beta of -0.48. The company has a fifty day moving average price of C$3.93 and a two-hundred day moving average price of C$4.26.

HLS Therapeutics (TSE:HLS) last announced its earnings results on Wednesday, August 12th. The company reported C($0.03) earnings per share (EPS) for the quarter. The firm had revenue of C$14.67 million during the quarter. HLS Therapeutics had a negative net margin of 15.26% and a negative return on equity of 14.39%. During the same period in the previous year, the business posted ($0.09) earnings per share. Sell-side analysts forecast that HLS Therapeutics Inc. will post -0.12 earnings per share for the current year.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.